SynthesisFrontiers in immunology2026
The risk association between systemic lupus erythematosus and glaucoma: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease that may damage multiple organs. About one-third of SLE patients have ocular manifestations. SLE as a potential risk factor for glaucoma has attracted attention, but existing study conclusions remain controversial. This meta-analysis aimed to evaluate the risk association between SLE and glaucoma and provide supportive evidence for the comorbidity follow-up of SLE patients. Methods: The PubMed, EMBASE and Web of Science databases from the establishment of the database to November 2025 were retrieved, and studies measuring the association between SLE and glaucoma risk by hazard ratio (HR), odds ratio (OR), relative risk (RR), incidence rate ratio (IRR) and 95% confidence interval (CI) were included. Two researchers independently screened the literature, extracted the data and evaluated the risk of bias in the included studies. Meta-analysis was conducted using RevMan 5.3 software. Results: Five cohort studies were included, involving 5516709 participants. Meta-analysis showed that SLE was associated with an increased risk of glaucoma (OR = 2.85, 95% CI: 1.26-6.47, Conclusions: Existing evidence suggests that SLE may be associated with an increased risk of glaucoma. Given the limitations of this study, more prospective studies with rigorous design and full control of confounding factors are needed for further verification. Systematic review registration: https://www.crd.york.ac.uk/prospero, identifier CRD420261303001.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.